Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 2 of 2

Imatinib, used to treat leukaemia, targets a receptor known as KIT that is critical to mast cell function. Researchers say that the findings indicate that targeting the KIT receptor and decrease mast cell counts could be an approach to treat severe asthma

The team found that patients randomly assigned to imatinib had a significantly greater reduction from baseline in airway responsiveness compared with those who received placebo.

Source  Shutterstock.com